Drugs / DMT210
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03003104 | Jan → Aug 2017 | rosacea | Dermata Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DMT210 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03003104 ↗ |
| Known as | DMT210 Gel | “The study evaluates the safety, tolerability, and efficacy of DMT210 Gel, 5% when applied twice daily for 12 weeks” NCT03003104 ↗ |
| Route | Topical | “DMT210 Topical Gel 5% applied to the face twice daily for 12 weeks” NCT03003104 ↗ |